Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Angiodynamics (ANGO) Revenue (2016 - 2026)

Angiodynamics' Revenue history spans 17 years, with the latest figure at $78.4 million for Q1 2026.

  • For Q1 2026, Revenue rose 8.91% year-over-year to $78.4 million; the TTM value through Feb 2026 reached $313.7 million, up 10.73%, while the annual FY2025 figure was $292.5 million, 3.76% down from the prior year.
  • Revenue reached $78.4 million in Q1 2026 per ANGO's latest filing, down from $79.4 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $91.1 million in Q2 2023 to a low of $67.5 million in Q3 2024.
  • Average Revenue over 5 years is $78.2 million, with a median of $78.7 million recorded in 2023.
  • Peak YoY movement for Revenue: rose 13.22% in 2022, then fell 22.06% in 2024.
  • A 5-year view of Revenue shows it stood at $85.4 million in 2022, then dropped by 7.44% to $79.1 million in 2023, then fell by 7.88% to $72.8 million in 2024, then increased by 9.04% to $79.4 million in 2025, then dropped by 1.27% to $78.4 million in 2026.
  • Per Business Quant, the three most recent readings for ANGO's Revenue are $78.4 million (Q1 2026), $79.4 million (Q4 2025), and $75.7 million (Q3 2025).